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: adverse drug reactions; opioids; pain management; pharmacogenomics; therapeutic drug monitoring Pain is a complex and subjective experience with multiple dimensions. It is also one of the most common reasons people seek medical care [1] . It is estimated that nine out of ten individuals regularly suffer from pain [2, 101] . However, pain is often undertreated leading to immense costs for society including lost productivity and unnecessary suffering. For example, inadequately managed acute pain can impair recovery from an injury or procedure, lead to medical complications and may progress to chronic pain [3] . Poorly treated chronic pain can lead to work absenteeism, unemployment and a diminished quality of life [102] . Many consensus opinions and guidelines have been developed for the management of acute and chronic pain [3] and cancer pain [4] , including those developed by the US Department of Health and Human Services. In addition, pain management is a focus of regulatory bodies such as the Joint Commission on Accreditation of Healthcare Organizations (JCAHO; IL, USA) [103] . Overall, there is a high priority mandated in the USA to provide appropriate and adequate pain management in patient care.
* Treatment of pain
Many strategies and modalities for the treatment of pain exist, but can be broadly categorized as pharmacologic and nonpharmacologic. Although there are several approaches to treating pain, pharmacotherapy using medications alone or in combination is the strategy most often used. In fact, one in five Americans use over-the-counter or prescription analgesics on a daily basis [2] .
Current basic analgesic strategies for chronic pain and cancer pain can be summarized by the WHO analgesic ladder (1990) in which NSAIDs or other non-opioid analgesics are used first, followed by a stepwise progression to stronger centrally acting analgesics [5] . Analgesics can be broadly categorized as: non-opioid, opioid and adjuvant analgesics. Non-opioids may be used in combination with opioids for their opioid-sparing effect, permitting the use of lower doses of opioids [6] . Opioids are primarily used to treat moderate to severe pain that has not responded to non-opioids alone. Although opioids have a higher analgesic potency and wider range of indications than any of the other medications for pain control, they remain underutilized [7] . There are many factors that are barriers to opioid prescribing and medication compliance with these medications, Download Document file:///C:/Users/HB/AppData/Local/Temp/Download Document.html including: concerns and lack of understanding of addiction, pseudoaddiction, tolerance, the risks of abuse and diversion and other potential side effects. Despite these concerns, opioids still play an essential key role in the treatment of pain [104] .
* Pharmacogenomics
Pharmacogenomics is the study of how genes influence the way a patient responds to drug therapy. Pharmacogenomics can be clinically useful in several important therapeutic settings including: * Use of medication cleared primarily by a polymorphic enzyme (e.g., antidepressants); * Use of medications with a narrow therapeutic index (e.g., aminoglycosides, immunosuppressants); * Use of prodrugs whose activity is dependent upon the metabolite formed by a polymorphic enzyme (e.g., codeine); * In situations when a patient demonstrates a suboptimal or unexpected response to therapy [8] .
The Mayo Clinic (MN, USA) is routinely offering pharmacogenetic testing of cytochrome P450s to help pinpoint genetic factors that influence a patient's response to certain antidepressants. The test does not predict which antidepressant will work best, but is being used to help suggest which ones may not work and which ones may have the greatest side effects. Pharmacogenomic testing is clearly not standard at all medical centers, but this may be slowly changing. The rationale behind genotyping is that it will lead to increased therapeutic effectiveness, safety and improved patient outcomes, while minimizing adverse reactions.
In general, the majority of therapeutic drugs used in pain management (i.e., codeine, dihydrocodeine, fentanyl, hydrocodone, methadone, morphine, oxycodone, tramadol and tricyclic antidepressants) are metabolized by polymorphic CYP450 enzymes such as CYP2D6, CYP3A4
and/or uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7) [9, 10] . The wide range of genetic polymorphisms of CYP2D6 can be categorized into four groups: ultrarapid metabolizers (UMs) containing multiple copies of the CYP2D6 gene; extensive metabolizers (EMs) with a single wild-type copy of the CYP2D6 gene; intermediate metabolizers (IMs) exhibiting decreased enzymatic activity; and poor metabolizers (PMs) with no detectable activity. Differences in drug metabolism can lead to severe toxicity or therapeutic failure by altering the relationship between the dose and steady-state blood concentration of the pharmacologically active drug. In fact, inherited differences in the metabolism and disposition of drugs and genetic polymorphisms in drug targets can have a greater influence on the efficacy and toxicity of medications than other clinical variables [11] . Although the majority of the population are EMs of CYP2D6 , 5-10% of Caucasians and 1-4% of most other ethnic groups have decreased CYP2D6 activity (PMs) and risk toxic effects if they receive the routine clinical dose of a drug inactivated by this enzyme [8, 12] . As a result, pharmacogenomics may serve as a tool for optimizing the action of medications in the treatment of various diseases and disorders, including pain management.
* Therapeutic drug monitoring
Despite the fact that analgesics comprise the largest category of pharmaceutical agents used in the USA, therapeutic drug monitoring (TDM) is not routinely used when prescribing analgesics as its role in the titration and monitoring of these medications is not well defined, and analgesics are generally considered to have a low therapeutic index. However, the reduction in analgesic toxicity is Download Document file:///C:/Users/HB/AppData/Local/Temp/Download Document.html important considering that the Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System shows that analgesics are the primary substance in 24% of all reported fatalities in this system [13] . Previously, TDM for analgesics had only been proposed for the following situations:
* To confirm or identify suspected drug toxicity; * To aid in the identification of an unknown drug ingested in unknown quantities; * To monitor select patient groups at greater risk for analgesic drug toxicity or drug-drug interaction;
* To confirm complete drug absorption and adequate drug elimination as an adjunct in drug overdose management [14] .
The goal of this study was to characterize the relationship between TDM and effectiveness of analgesics metabolized by CYP2D6 (i.e., tramadol, hydrocodone, oxycodone and methadone), including the pharmacogenomic CYP2D6 genotype as an independent variable. The relationship between steady-state drug concentrations (Css) and clinical effectiveness (degree of pain relief) or adverse drug reactions (ADRs), along with the patient's CYP2D6 genotype, was examined. It was hypothesized that PMs taking analgesics metabolized by CYP2D6 would have higher plasma concentrations of the parent drug (whether active or inactive), and be more likely to experience ADRs and therapeutic failure for agents requiring CYP2D6 metabolism to convert a prodrug to the active metabolite.
Materials & methods

* Study design & subjects
This study was approved by the Human Research Protection Office and Institutional Review Board of the Medical College of Wisconsin and Froedtert Hospital (WI, USA). Written informed consent was obtained from all subjects during their routine visits at one of the three area pain management clinics (Midwest Comprehensive Pain Care, Zablocki VA Hospital [WI, USA], and Froedtert Hospital). Male and female patients who were being treated for chronic pain and were prescribed an opioid, or opioid-like medication (hydrocodone, methadone, oxycodone or tramadol) metabolized by CYP2D6, were eligible to participate in the study. Therefore, patients on long-term opioid therapy for chronic painful conditions, such as osteoarthritis of the spine, were included. Other inclusion criteria included that the patient was at least 18 years of age and willing to comply with the study protocol. Exclusion criteria included patients receiving methadone maintenance therapy.
Patients who were newly prescribed (<1 month) an opioid were required to have two blood samples drawn. The initial blood sample was used to determine the CYP2D6 genotype of the patient, while the second blood sample (at least 1 month after reaching a stable titration for pain relief) was used to determine the Css of the opioid in the patient's plasma. Established patients who were already on opioids for at least 1 month and had reached a stable titration for pain relief had only one blood sample drawn, which was used to determine both the plasma drug concentration and CYP2D6 genotype of the patient.
* Clinical assessment
Clinical assessment of each patient included a detailed history and physical examination with emphasis on neurological, cognitive and functional assessment. Standard scales such as the verbal/visual analog scale (VAS) were employed for the assessment of pain at every patient's clinic visit. A VAS scale is used with the categorization of relief from beginning of titration to stable dose. Pain relief was defined as follows: no pain relief was no change in the VAS score from baseline, partial pain relief was a decrease in the VAS score of 2 or more from the initial visit, while complete pain relief was a VAS score of 0. The categories of partial, complete and no relief were chosen and defined (as is common in other pain studies). However, pain assessment is subjective so a 9 to 7 may be another person's 3 to 1. In addition, change from each patient was evaluated for possible side effects using an investigator-developed questionnaire at the initiation and subsequent visits. Common opioid side effects included: drowsiness, trouble concentrating, constipation and nausea/vomiting. Currently, self report is the primary and best indicator of side effects that physicians have. Furthermore, the consumption of prn (as needed) analgesic medication for breakthrough pain and the information recorded in the patient's daily pain log (or self-reported pain) was used to determine the effectiveness of the pain management therapy. Functional improvement, the ability to perform daily living tasks and range of motion were also used to determine the effectiveness of therapy.
* Genotyping
DNA was extracted from ethylenediaminetetraacetic acid (EDTA) whole blood using the Puregene ® DNA isolation kit (Gentra Systems, MN, USA). The DNA was then quantified and checked for purity by spectrophotometric methods.
All samples were analyzed for variants in CYP2D6 (*3 , *4 , *6 , *7 and *8 ) using Pyrosequencing ® (Qiagen, Hilden, Germany) technology as previously described [15] . Briefly, nested PCR was performed with a single fragment in the primary PCR and two separate reactions in the second PCR. The Pyrosequencing analysis was then run as a duplex (*3 and *7) and triplex (*4 , *6 and *8 ) assay using a PSQ[trademark] HS96A system and software (Biotage, Uppsala, Sweden). In addition, the CYP2D6 gene deletion (*5 ) and duplication (*2xn ) were detected using Pyrosequencing technology as previously described [16] . Briefly, an equivalent region of CYP2D6 and the pseudogene CYP2D8 were amplified by PCR and analyzed in two common Pyrosequencing reactions in which peaks specific for each respective gene were generated and peak heights compared. The heights of specific peaks from CYP2D8 , which occur as a single copy in all alleles, are used as a reference for CYP2D6 -specific peak heights. This relative quantification approach allows the distinction of zero to four CYP2D6 genome copies.
* Reagents
Hydrocodone, hydrocodone-D 3 , oxycodone, oxymorphone, methadone and tramadol were purchased from Cerilliant (TX, USA). HPLC-grade methanol was purchased from Fischer Scientific (NJ, USA). Ammonium acetate was purchased from ICN Biomedicals Inc. (OH, USA). Formic acid was purchased from Mallinckrodt Baker Inc. (KY, USA). A Barnstead[trademark] Fi-streem glass still (Thermo Scientific, MA, USA) water purification system was used to obtain purified water for the HPLC solvent.
* HPLC equipment/conditions
Hydrocodone, oxycodone, oxymorphone, methadone and tramadol were extracted in a single step from alkalized plasma into N -hexane/isoamylalcohol (99/1, v/v) following a previously published protocol [17] . Briefly, sample aliquots (500 µl plasma) were mixed with 100 µl of 1 M potassium ownload Document file:///C:/Users/HB/AppData/Local/Temp/Download Document.html carbonate and 800 µl of N -hexane/isoamylalcohol containing the internal standard (50 µg/l hydrocodone-D 3 ) in a 1.5 ml microcentrifuge tube. After vortex mixing, the samples were centrifuged for 5 min at 13,000 rpm. The supernatant was transferred to another microcentrifuge tube and loaded onto a 24-well sample plate for HPLC-mass spectrometry (MS)-MS analysis. A Waters Alliance 2795 HPLC system was used. Chromatography was achieved using a Discovery ® Cyano HPLC column (Sigma Aldrich, MO, USA; 15 cm × 4.6 mm, 5 µm), maintained at 30°C. The injection volume was 20 µl with a flow rate of 500 µl/min. The opioids were eluted isocratically using 2 mM ammonium acetate containing 0.1% formic acid in water:methanol with 0.1% formic acid (60:40). The total analysis time was 5 min. All aspects of the system operation and data acquisition were controlled using MassLynx NT 3.5 software.
* MS equipment/conditions
A Micromass Quattro micro[trademark] triple quadrupole tandem mass spectrometer (Waters Corp., MA, USA) was used for all analyses. Ionization was achieved using electrospray in the positive ion mode. The following conditions were found to be optimal for the analysis of the opioids: capillary voltage, 1.0 kV; source block temperature, 100°C; and desolvation gas (nitrogen) heated to 300°C. 
* Statistical analysis
A Fisher's exact test was used to compare the prevalence of variant CYP2D6 alleles in the chronic pain patients in the pain management clinics to those previously published in for the general population. In addition, the average Css of each drug (oxycodone, hydrocodone, tramadol and methadone) was compared between each of the CYP2D6 genotypes (EM, IM and PM) using the one-way analysis of variance (ANOVA). Statistically significant results had a p-value of less than 0.05.
Results
A total of 61 chronic-pain patients from three separate pain management clinics were enrolled from November 2002 until February 2004. Of the 61 patients, 51% were male and 49% were female. The average age of all the chronic pain patients was 51, but ranged from 25 to 86. The most common diagnosis and reason the patient's sought pain relief was due to chronic lower back pain (38%), followed by migraines (8%). Since the prevalence of various genetic polymorphisms varies depending on ethnic background, it is important to note that the majority of chronic pain patients enrolled in the study were Caucasian (90%) followed by African-American (8%), Hispanic (1%) and American-Indian (1%). Table 1 shows the demographics, diagnosis, pain management therapy and CYP2D6 genotype of all 61 subjects. The most commonly prescribed opioid, alone or in combination, for pain management was oxycodone (54%) followed by tramadol and methadone (31 and 28%, respectively). The vast majority of patients included in this study (75%) were prescribed either an antidepressant or an anticonvulsant concomitantly with opioids. Only 15% of all the patients had an opioid as their sole therapeutic agent for pain therapy. The most commonly ownload Document file:///C:/Users/HB/AppData/Local/Temp/Download Document.html prescribed opioid for monotherapy was oxycodone (50%) followed by tramadol (24%), methadone (17%) and hydrocodone (9%).
Due to the risk of abuse or diversion, pain management patients who are being prescribed opioid medications usually have their urine monitored to determine compliance. In this study, the ability to detect the opioid in the patient's plasma was used as an indicator of compliance. Compliance was defined as detectable plasma concentrations (&ge;1 ng/ml) of the prescribe opioid(s). Patients with undetectable ( IM > EM. However, the Css of oxycodone for PMs was actually lower than both the IMs and EMs. Upon further investigation, it was discovered that the two PM patients had skipped one or more doses of their oxycodone. Therefore, the Css of oxycodone was falsely decreased and a true Css value was not measured.
Discussion
* Clinical usefulness
In the past decade, several studies have examined the clinical significance of genotyping CYP2D6 polymorphisms. Pharmacogenomics may be clinically important if the pharmacokinetic variability is relevant and CYP2D6 is the major route of metabolism for the compound of interest [18] . In other words, if a characterized polymorphic enzyme primarily determines the elimination or activation of a drug, genotyping might provide additional useful information. As a result, genotyping CYP2D6 as part of the standard professional practice (personalized medicine) may be good medical practice for prescribing or determining the dosage of pain medications, such as opioids.
Currently, application of pharmacogenomics in the clinical setting is becoming more common for other diseases and shows great promise in providing clinicians with the ability to more appropriately select drug therapy, predict therapeutic responses and identify those at high risk for side effects; examples include coagulation disorders, depression and chemotherapy. Recently, the US FDA approved an updated label for warfarin, which includes pharmacogenomic information [105] .
Ultimately, genotyping patients prescribed warfarin may become standard to detect abnormal metabolism, which would put a patient at higher risk for complications [19] . Specific indications for genotyping and/or conventional TDM have been proposed for the prescribing of antidepressants (i.e., paroxetine and mirtazapine) [20, 21] and neuroleptics/antipsychotic medications [22] . In addition, genotyping has already become standard practice in some major cancer treatment centers (i.e., Mayo Clinic and St Jude Children's Research Hospital, TN, USA) [23] .
* Pharmacogenomics & pain
Interindividual differences in the perception of pain have been acknowledged clinically for over a century. Pain patients often report that they are 'more sensitive' to medications. In recent years, the differences in analgesic response to various medications are beginning to be understood. In fact, PMs have been postulated to be more susceptible to pain than EMs because of a defect in synthesizing endogenous opioids [24] .
Genetic differences in the metabolism of pain medications like codeine have been elucidated by pharmacogenomics. Codeine, in combination with acetaminophen, is one of the most commonly used preparations for the treatment of moderate pain in children [25] and is in a variety of antitussive preparations [26] . Codeine has a favorable pharmacokinetics profile in that it is well absorbed [27] ownload Document file:///C:/Users/HB/AppData/Local/Temp/Download Document.html and reaches peak plasma concentrations after approximately 1 h [28] . Codeine works in a similar manner to other opioids like morphine, hydrocodone and oxycodone by binding to µ-and &kappa;-opioid receptors to produce analgesia and euphoria [25] . However, codeine itself has a very low affinity for the opioid receptors making it a weak analgesic (only one-tenth the potency of morphine) [27] . It has been suggested that the primary analgesic response from codeine results from the 10% that is metabolized to morphine by CYP2D6 [29, 30] . Therefore, patients with no or reduced CYP2D6 activity may not achieve adequate morphine concentrations for analgesia. As a result, PM patients will have limited pain relief and may request larger doses, which could lead to toxicity or be misinterpreted as drug addiction. This concept is supported by another study where CYP2D6 PMs recovering from abdominal surgery required higher loading doses of tramadol, subsequent tramadol consumption and a need for rescue medication compared with patients carrying at least one wild-type allele [31] . Therefore, the proportion of nonresponders was significantly increased in the PM group compared with the functionally active group (46.7 vs 21.6%) [31] . Unfortunately, no CYP2D6 PMs who were being prescribed tramadol for pain management
were found in the current study.
In addition, genetic variations can also occur in drug absorption/transport and drug targets leading to variability in response to pain therapies. For example, one study showed interindividual variations in µ-opioid receptor gene expression and responses to painful stimuli and opioid drugs, probably due to a genetic polymorphism in the transcription regulating region of the gene [32] . Therefore, µ-opioid receptor gene expression can affect the analgesic potency of opioids like morphine making it a candidate for susceptibility or resistance to pain. In fact, a SNP in the µ-opioid receptor at position 118 (A118G) results in a variant receptor that binds [beta]-endorphins approximately three-times more tightly than the common allelic form. As a result, [beta]-endorphin is almost three-times more potent in individuals with the polymorphism. It may also be clinically relevant to look at genetic polymorphisms in UGTs since many pain medications undergo conjugation and these variations can affect the water solubility and elimination of these drugs. Other candidate genes including catechol-O -methyltransferase, melancortin-1 receptor and guanosine triphosphate cyclohydrolase have been investigated and associations were found with sensitivity to pain as well as with analgesic requirements in states of acute and chronic pain [33] . In the end, the clinical efficacy and side effects of pain management drugs will depend upon the sum of the genetic factors that affect both pharmacokinetic and pharmacodynamic properties.
* Pain treatment & individualization
Pharmacotherapy remains the mainstay for the treatment of pain. Even with standardized dosing of prescription drugs, varied clinical responses are seen in patients, ranging from no effect to complete pain relief, or even unforeseen serious adverse drug effects. People differ in their genetic make-up and consequently in their response to drugs. It is estimated that the most commonly used drugs will only be effective in 30-60% of the patients with the same disease, with a subset of these patients suffering severe ADRs [34] . This is important since ADRs rank between the fourth to sixth leading cause of death in the USA and have over a US$100 billion dollar annual economic impact [35] .
Pharmacogenomics has the potential to individualize pain treatment and help avert unintentional drug overdoses. Individualization of a pain management regimen begins with the selection of an appropriate drug. Factors that guide this process include: characteristics of the pain, characteristics of the therapeutic agent and patient factors (co-existing diseases and other medications) [36, 37] . The problem could be more complex considering that patients are often on multiple medications that may also induce or inhibit the cytochrome P450 system, potentially putting PMs and IMs at more risk.
Individual differences may explain the lack of effect of a medication, or the inability to use it safely. ADRs may be as serious as death in patients unable to metabolize the medication safely. Previous studies have already postulated that PM patients may be at an increased risk for overdose. An illustrative case is the study revealing a higher prevalence of PMs and IMs seen in oxycodonerelated deaths at the Milwaukee County Medical Examiner's office (WI, USA) [38] . Another postmortem study showed that the average fentanyl concentration and the metabolic ratios of fentanyl:norfentanyl of CYP3A4*1B wild-type and 3A5*3 homozygous variant cases were higher than those of the CYP3A4*1B variant cases [39] . The conclusion of both forensic studies was that genotyping provided a more definitive interpretation of the toxicity and may serve as a molecular autopsy acting as an adjunct in certifying death cases involving pain medications [38, 39] .
In this study, pharmacogenomics and TDM both provided additional information that could be valuable to pain management physicians. For oxycodone, the TDM clearly showed that patients experienced complete or partial pain relief only when the plasma Css was at least 15-32 ng/ml. This data is consistent with other published reports, which report the therapeutic window for oxycodone as 20-50 ng/ml [40] . Therefore, TDM could be used to evaluate patients that are not responding to oxycodone pain management therapy to see if they are achieving therapeutic concentrations. On the other hand, the pharmacogenomic information could be used to predict the dosage needed to achieve therapeutic Css, or even be used to predict who may be more likely to experience an ADR if started on the standard dose. Using the CYP2D6 genotype, a PM might either be started on a lower dose of an opioid metabolized by CYP2D6 or placed on an alternative medication that is metabolized by a different pathway (i.e., fentanyl). Together, the TDM and pharmacogenomic information could guide the selection and dosage of the opioid to minimize side effects and maximize therapeutic effectiveness.
This study also revealed several important issues that pain management physicians face daily. First of all, most patients followed by pain management specialists are rarely prescribed only one medication (opioid) as their sole therapy. Most patients are also prescribed an adjuvant analgesic, like neuromodulators. The issue of drug-drug interactions must always be addressed since some co-medications might induce or inhibit the metabolism of the other opioid medications leading to complications (i.e., failed therapy or ADR). In this study, only 15% of the patients were on an opioid as the sole therapy and most had either an anticonvulsant and/or antidepressant prescribed as adjunct therapy. Fluoxetine, a commonly prescribed antidepressant, is a very potent inhibitor of CYP2D6 and could make an EM look like a PM. As a result, the Css and any ADRs had to be interpreted in lieu of this information (potential drug-drug interactions). The other issue highlighted in this study was compliance to prescribed opioids. Compliance is a real problem faced by pain management physicians and occurs with any type of therapy. As a result, compliance is another confounder that must be considered when interpreting the Css.
Finally, 8% of all the patients reported an ADR to their prescribed opioid. The most commonly reported side effects were drowsiness and nausea. Of all the individuals that reported ADRs, 80% (four out of five) had impaired CYP2D6 metabolism based on their CYP2D6 predicted phenotype. The only individual that experienced an ADR, but had normal CYP2D6 metabolism, was consuming several medications that were at least partially metabolized by CYP2D6 (methadone, oxycodone, amitriptyline and cyclobenzaprine). It is important to note that methadone is both a substrate and an Download Document file:///C:/Users/HB/AppData/Local/Temp/Download Document.html inhibitor of CYP2D6 . Therefore, potential drug-drug interactions might explain the observed toxicity. Alternatively, there are over 75 known CYP2D6 mutations and the most prevalent mutation found in populations of this patient's ethnicity was not part of the genetic test panel. As a result, this individual may have had a polymorphism that was not tested for and truly be an impaired CYP2D6 metabolizer.
Conclusion
It is estimated that almost half of all Americans have at least one family member who suffers from chronic pain due to a specific illness or medical condition [41] . An example is back pain [42] , which has a lifetime prevalence of 60-80% and results in significant physical, psychological and financial consequences [43] . In general, pain costs Americans more than US$100 billion each year in healthcare costs and lost productivity [106] .
Pharmacogenomics has the potential to allow clinicians and researchers to prescribe and design less toxic and more efficacious medications based on an individual's genotype. This study showed that the majority of individuals that experienced ADRs had impaired CYP2D6 metabolism. Furthermore, PMs and IMs generally had higher Css and TDM could potentially guide oxycodone therapy. As a result, personalized medical therapy for chronic pain patients based on their CYP2D6 genotype may predict which drug a patient may respond to without suffering any needless side effects and help them return to a normal, productive life. Personalized medicine for pain management offers the possibility of optimized pain control, with proper drug selection and dose determination, with increased patient safety and decreased risk of serious, potentially life-threatening side effects. Overall, this study illustrates that additional pain management studies investigating the role of pharmacogenomics and TDM need to be conducted using larger sample sizes to prove statistical significance. Concentrations expressed as the mean ± the standard deviation.
Css: Steady-state concentration.
Executive summary
Phamacogenomics & pain * Pain management patients do not have a significantly different prevalence of genetic polymorphisms in a key opioid metabolizing enzyme, CYP2D6 , compared with the general population.
Pain treatment & individualization
* A trend was observed in pain management patients where CYP2D6 poor metabolizers had higher opioid steady-state drug concentrations compared with extensive metabolizers (i.e., poor metabolizers > intermediate metabolizers > extensive metabolizers).
* Therapeutic drug monitoring may be useful in pain management patients since patients reported complete or partial pain relief only when the plasma oxycodone steady-state drug concentration was at least 15-32 ng/ml.
* Genotyping pain management patients may identify individuals more likely to experience side effects, since 80% of the patients that reported adverse drug reactions had impaired CYP2D6 drug metabolism. 
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